469 related articles for article (PubMed ID: 28375875)
1. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
3. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
[TBL] [Abstract][Full Text] [Related]
4. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
[TBL] [Abstract][Full Text] [Related]
5. Primary resistance to integrase strand-transfer inhibitors in Europe.
Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.
Alvarez M; Casas P; de Salazar A; Chueca N; Guerrero-Beltran C; Rodríguez C; Imaz A; Espinosa N; García-Bujalance S; Pérez-Elías MJ; García-Alvarez M; Iribarren JA; Santos J; Dalmau D; Aguilera A; Vinuesa D; Gutiérrez F; Piérola B; Molina JM; Peraire J; Portilla I; Gómez-Sirvent JL; Olalla J; Galera C; Blanco JR; Riera M; García-Fraile L; Navarro G; Curran A; Poveda E; García F;
J Antimicrob Chemother; 2019 Jun; 74(6):1693-1700. PubMed ID: 30838386
[TBL] [Abstract][Full Text] [Related]
7. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
8. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
[TBL] [Abstract][Full Text] [Related]
9. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
10. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.
Marcelin AG; Grude M; Charpentier C; Bellecave P; Le Guen L; Pallier C; Raymond S; Mirand A; Bocket L; Fofana DB; Delaugerre C; Nguyen T; Montès B; Jeulin H; Mourez T; Fafi-Kremer S; Amiel C; Roussel C; Dina J; Trabaud MA; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Maillard A; Ferre V; Descamps D; Calvez V; Flandre P;
J Antimicrob Chemother; 2019 May; 74(5):1368-1375. PubMed ID: 30789205
[TBL] [Abstract][Full Text] [Related]
11. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G
J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.
Davy-Mendez T; Napravnik S; Zakharova O; Wohl DA; Farel CE; Eron JJ
AIDS; 2019 Jun; 33(7):1187-1195. PubMed ID: 30870198
[TBL] [Abstract][Full Text] [Related]
15. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
[TBL] [Abstract][Full Text] [Related]
16. Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection.
Ambrosioni J; Nicolás D; Manzardo C; Agüero F; Blanco JL; Mosquera MM; Peñafiel J; Gatell JM; Marcos MA; Miró JM
J Antimicrob Chemother; 2017 Jan; 72(1):205-209. PubMed ID: 27624569
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
19. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
